Synthetic cytokine receptor (SyCyR) (SyCyR)

Synthetic cytokine receptors (SyCyRs) are engineered signaling proteins designed to provide precise, selective control over the activity of therapeutic cells, such as T-cells or NK cells (Sockolosky et al., 2018, Science). These receptors are typically modified versions of natural cytokine receptors, such as the IL-2, IL-12, or IL-7 receptors, where the extracellular binding domain is mutated to recognize a specific orthogonal ligand that does not interact with wild-type receptors (Synthekine, 2023). This decoupling allows for the selective activation of engineered cells within a patient without triggering systemic immune responses or off-target effects on endogenous cells that lack the synthetic receptor (Moraga et al., 2015, Nature Reviews Immunology). Upon binding their specific synthetic ligand, SyCyRs dimerize and initiate downstream signaling pathways, most commonly the JAK/STAT pathway, to promote cell survival, proliferation, and effector function (Sockolosky et al., 2018). This technology is a cornerstone of next-generation adoptive cell therapies, particularly in oncology, where it helps overcome the immunosuppressive tumor microenvironment by providing necessary growth signals (Kalos & June, 2013, Immunity). By using SyCyRs, clinicians can tune the strength and duration of the immune response by adjusting the dosage of the administered orthogonal cytokine, offering a safer and more controlled alternative to systemic high-dose cytokine therapy (Synthekine, 2023).

Other names

Orthogonal cytokine receptorEngineered cytokine receptorChimeric cytokine receptorOrtho-receptorSynthetic Notch receptor (synNotch)

Ligand-induced dimerization of engineered receptor subunits to initiate intracellular signaling cascades specifically in cells expressing the synthetic receptor.